RxDoctor Payments Data

Donna Rocha, MD

Psychiatry · Springdale, ARNPI 1780666495

Payments from drug & device makers

$1,261in general payments, 2019–2025

Across 88 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$241
  • AbbVie$187
  • Alkermes, Inc.$173
  • Neurocrine Biosciences, Inc.$142
  • Lundbeck LLC$110
  • Johnson & Johnson$106
  • plus $302 from 6 others

What the payments were for

  • Food & beverage$1,24899%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,261 in reported general payments places this provider in the 65th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas

Medicare billing

Part B allowed, 2024
$44,357
Medicare patients
78
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate42$351,452
AustedoDeutetrabenazine26$197,497
Invega SustennaPaliperidone Palmitate54$170,021
VraylarCariprazine Hcl100$148,702
AristadaAripiprazole Lauroxil24$80,004
Abilify MaintenaAripiprazole22$57,400
Lurasidone Hcl110$39,598
Risperdal ConstaRisperidone Microspheres23$29,226
TrintellixVortioxetine Hydrobromide47$25,892
Aripiprazole248$23,497
LybalviOlanzapine/Samidorphan Malate12$18,990
VyvanseLisdexamfetamine Dimesylate34$12,906
Clozapine146$11,409
BelsomraSuvorexant18$8,170
Chlorpromazine Hcl36$7,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$142$351,45242 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$106$199,24777 claims
Teva Pharmaceuticals USA, Inc.Austedo$11$197,49726 claims
AbbVieVraylar$187$148,702100 claims
Alkermes, Inc.Aristada, Lybalvi$173$98,99436 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$241$57,40022 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$48$38,79781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 psychiatry providers in Arkansas.

Other psychiatry in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →